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Abstract 
Background: Malaria is one of the most lethal and life-threatening infectious diseases in the world, causing more 
than half a million deaths annually. Treatment with mefloquine and artesunate is currently recommended by the 
World Health Organization, and was historically the first artemisinin-based combination therapy used clinically for 
treatment of Plasmodium falciparum. The problem of poor-quality medicines, such as counterfeit and sub-standard 
anti-malarials, is a worldwide issue; therefore, it is essential to develop rapid, low cost, solvent-free, and reliable meth-
ods for routine quality control for these drugs. The aim of this study was to develop and validate a novel multivariate 
method for direct simultaneous quantification of mefloquine and artesunate in tablets by diffuse reflectance, middle 
infrared spectroscopy and partial least squares regression (MIR-PLS).
Methods: Diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS) and partial least squares regres-
sion were applied for simultaneous quantification of artesunate and mefloquine in tablets provided by the Brazil-
ian Government. The model was obtained with full spectra (4000–400 cm−1) preprocessed by first derivative and 
Savitzky-Golay smoothing followed by mean centring, and built with three latent variables. The method was validated 
according to Brazilian and international guidelines through the measuring of figures of merit, such as trueness, preci-
sion, linearity, analytical sensitivity, selectivity, bias, and residual prediction deviation. The results were compared to an 
HPLC–MS/MS method.
Results: The MIR-PLS method provided root mean square errors of prediction lower than 2.0 mg per 100 mg of 
powder for the two analytes, and proved to be valid according to guidelines for analytical methods that use infrared 
(IR) spectroscopy with multivariate calibration. For the samples obtained from Brazilian healthcare units, the method 
provided results statistically similar to those obtained by HPLC–MS/MS.
Conclusion: MIR-PLS was found to be suitable for the quality control of these drugs. It is fast, does not use solvents, 
and does not generate chemical waste. Furthermore, the proposed method may be transferred and developed for 
use in portable equipment, increasing the possibilities for assessing the quality of these drugs.
Keywords: Artesunate, Mefloquine, DRIFTS, Multivariate analytical, PLS, Analytical validation, Quality control
© 2016 Marson et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  pontarolo@ufpr.br 
Laboratório de Controle de Qualidade, Departamento de Farmácia, 
Universidade Federal do Paraná, 8021 Av Prefeito Lothário Meissner, 632, 
Curitiba, Paraná 80210-170, Brazil
Page 2 of 8Marson et al. Malar J  (2016) 15:109 
Background
Malaria is a human infection caused by some protozoan 
parasites of the genus Plasmodium [1]. Many species are 
known to infect humans, and the most dangerous is Plas-
modium falciparum, responsible for the most severe and 
fatal cases [2, 3]. Recognized as a serious public health 
problem worldwide, 3.3 billion people are at risk of being 
infected with malaria and developing disease. In 2013, 
198 million cases of malaria were recorded, and the dis-
ease led to between 367,000 and 755,000 deaths [3].
Treatment is based on inhibiting the life cycle of the 
parasite. Currently, in order to increase the spectrum of 
therapeutic action and its effectiveness, as well as pre-
venting anti-malarial drug resistance, the World Health 
Organization (WHO) recommends that artemisinin-
based combination therapy (ACT), such as artesunate 
(ARS) and mefloquine (MFQ), be used for the treatment 
of uncomplicated P. falciparum malaria [3, 4]. Its mecha-
nism of action involves the interruption of the erythro-
cytic schizogony cycle, destruction of latent forms of the 
parasite in the tissue cycle, and stopping the growth of 
the sexual form [5]. ACT consists of the use of two drugs 
with different modes of action, combining the immedi-
ate effect of an artemisinin-derivative that rapidly clears 
asexual blood-stage parasites and gametocytes, as well as 
a drug that has a longer half-life, thus eliminating resid-
ual parasites [6].
ARS-MFQ fixed-dose combination tablets are the 
most common ACT treatment of uncomplicated fal-
ciparum malaria in Brazil [7]. Two kinds of tablet are 
currently available: one containing 25  mg of ARS and 
55 mg of MFQ (corresponding to 50 mg of mefloquine 
base), and one containing 100 mg of ARS and 220 mg 
of MFQ (corresponding to 200 mg of mefloquine base) 
(Fig. 1).
Anti-malarials are among the most widely taken drugs 
in tropical countries, and have been particularly tar-
geted by counterfeiters. The use of counterfeit drugs or 
sub-standard anti-malarial drugs can increase instances 
of morbidity, adverse effects and mortality due to exces-
sive dose, presence of potentially toxic ingredients 
or pathogenic contaminants. Also, sub-therapeutic 
amounts of active ingredients contribute significantly to 
selection of resistant parasites and, thus, resistance to 
anti-malarial drugs [8]. Quality control of anti-malarial 
drug preparations may help to ensure treatment efficacy 
and avoid development of resistance to anti-malarial 
drugs [9].
Several methods for the simultaneous quantification 
these drugs can be found in the literature, such as ultravi-
olet (UV) spectrophotometry [10, 11], high performance 
liquid chromatography (HPLC) with UV spectropho-
tometry detection [12, 13], high performance thin layer 
chromatography (HPTLC) with UV spectrophotometry 
detection [13, 14], and HPLC coupled with tandem mass 
spectroscopy (HPLC–MS/MS) [15]. Despite being very 
commonly used, no methods for quality control of avail-
able products are described in the pharmacopoeias [16–
19]. There are no methods using infrared (IR) associated 
with multivariate calibration for these drugs can be found 
in the scientific literature. Furthermore, this method pro-
vides direct and fast analysis, and is low cost and solvent 
free.
Methods based on diffuse reflectance infrared Fourier 
transform (DRIFT) middle infrared spectroscopy (MIR) 
and near infrared (NIR) spectroscopy have been adopted 
in the pharmaceutical industry for raw material test-
ing and process monitoring, and have become a reliable 
alternative for the quality control of active pharmaceu-
tical ingredients (APIs) [20–26]. Due to the significant 
overlap of IR bands, univariate techniques have limita-
tions. However, these limitations can be circumvented 
through the use of multivariate calibration tools. The 
combination of IR spectroscopy and multivariate calibra-
tion, such as partial least squares (PLS) regression, has 
emerged in the last decade as a promising alternative 
for the quality control of APIs [27]. Furthermore, IR in 
combination with multivariate calibration tools has sig-
nificant advantages in terms of speed, cost and reliabil-
ity of analysis. Perhaps most importantly, no solvent is 
required by the technique.
The aim of this work was to develop and validate a 
simple and rapid multivariate method for direct simul-
taneous determination of ARS and MFQ in powdered 
samples of anti-malarial tablet formulations using diffuse 
reflectance MIR spectroscopy and PLS. The results of the 
multivariate method (MIR-PLS) were compared with the 
results obtained using HPLC–MS/MS [15].
Fig. 1 Chemical structures of artesunate (ARS) and mefloquine 
(MFQ)
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Methods
Samples and chemicals
ARS, MFQ and ARS-MFQ fixed-dose combination tab-
lets were provided by Farmanguinhos/Fundação Oswaldo 
Cruz (Rio de Janeiro, RJ, Brazil). The ARS standard was 
obtained from Farmacopeia Brasileira (>98.8  %) (Bra-
sília, DF, Brazil), The MFQ-hydrochloride standard was 
obtained from Sigma-Aldrich (>98.0  %) (St Louis, MO, 
USA). Microcrystalline cellulose was obtained from DEG 
(São Paulo, Brazil), and croscarmellose sodium and mag-
nesium stearate were obtained from Indukern do Brasil 
Química Ltd (São Paulo, Brazil). HPLC grade acetoni-
trile and methanol were purchased from Tedia (Fair-
field, USA). Formic acid was purchased from Carlo Erba 
Reagenti, Rodano, Italy (>99.0  %). Ultrapure water was 
obtained using a Milli-Q purification system from Mil-
lipore (Bedford, MA, USA). The tablets had the formu-
lation composition: 100 mg of ARS and 220 mg of MFQ 
(corresponding to 200 mg of mefloquine base) per tablet. 
The quantitative compositions of the excipients are not 
publicly available.
Apparatus and software
The spectral dataset was acquired from a Bruker 
Alpha Fourier transform infrared (FTIR) spectrom-
eter equipped with a diffuse reflectance accessory, 
and under controlled temperature (20.0 ±  0.2  °C) and 
humidity (45–55  %). The spectra were obtained in 
absorbance mode using OPUS (Optical User Software) 
for windows (version 6.0, Brucker Optik, Bremen, Ger-
many). Data were handled using OPUS, MATLAB soft-
ware (version 7.13, The Math-Works, Natick, USA), 
PLS Toolbox (version 6.5, Eigenvector Technologies, 
Manson, USA), and Statistica 10.0 software (StatSoft, 
Oklahoma, USA).
HPLC–MS/MS analyses were performed on an Agilent 
1200 HPLC system (Agilent Technologies, Santa Clara, 
CA, USA) that consisted of a G1312B binary pump, a 
G1379B degasser and a G1316B column oven. This appa-
ratus was connected with a CTC sample manager (Model 
2777, Waters, Milford, MA, USA). The mass spectrom-
eter coupled to the HPLC system was a triple quadrupole 
API 3200 from Applied Biosystems MDS Sciex Instru-
ments (Foster City, CA, USA) equipped with a syringe 
pump (Harvard Apparatus, Holliston, MA, USA) and an 
electrospray (ESI) ion source. The data acquisition was 
performed with MS Workstation by Analyst 1.4 software 
(MDS Sciex, Concord, Ontario, Canada) [15].
Experimental design
Thirty-seven powder samples were prepared according 
to a central composite design (CCD) (αrotability = 1.6818; 
αortogonality =  1.2872) with three factors (ARS, MFQ and 
the majority excipient), and five levels plus a central 
point. The number of samples for calibration must be 
equal to 6 ×  [the number of latent variables (LV) +  1] 
and the number of validation samples equal to 4 ×  LV, 
according to the American Society for Testing and Mate-
rials (ASTM) recommendations, as depicted in Fig.  2 
[28].
The total mass of each sample was fixed at 100.0 mg, the 
central point of the CCD corresponds to 23.3 mg of ARS 
and 51.4 mg of MFQ per 100 mg of sample. The ranges 
of ARS and MFQ were varied from ca. 75.0–125.0 % of 
their nominal contents in the ARS-MFQ fixed-dose 
combination tablets. In the case of the minority excipi-
ents (croscarmellose sodium and magnesium stearate), 
was chosen not to vary their concentrations owing their 
low concentrations in the formulation. For the majority 
excipient microcrystalline cellulose, the concentration 
range was sufficient to ensure a final mass equivalent to 
100.0 mg of sample, as defined.
Sample preparation
The powder samples of experimental design were 
weighed with an analytical balance (±0.0001 g) and man-
ually homogenized with a pestle and mortar. The spectra 
of the samples were recorded from 4000 to 400 cm−1 as 
the average of 32 scans and with a resolution of 4 cm−1. 
To evaluate repeatability, six replicates of samples from 
the central point were also obtained. To estimate inter-
mediate precision, the results were compared with simi-
lar replicates obtained on another day by a different 
analyst. Fifty spectra of the empty cell were recorded to 
measure the instrumental noise.
The multivariate calibration model development
The multivariate calibration model was developed 
using PLS regression. Several models were built using 
algorithm PLS1 (models for only one API) and PLS2 
(models for 2 API simultaneously), cross-validation 
Fig. 2 Experimental central composite design (CCD) used for varia-
tion of active pharmaceutical ingredient contents, artesunate (ARS) 
and mefloquine (MFQ). Samples of calibration set are represented by 
circles and validation set by triangles
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(leave-one-out), and the combination of different pre-
processing methods. Models were constructed using 
the entire spectrum, restricted to using the leading 
bands of each analyte and also through the technique 
of intervals PLS (iPLS). The best models were chosen 
based on the value of the root mean square of calibra-
tion (RMSEC) and the root mean square of prediction 
(RMSEP).
Analysis of ARS‑MFQ fixed‑dose combination tablets
The content of ten tablets with 100  mg of ARS and 
220 mg of MFQ (corresponding to 200 mg of mefloquine 
base), was crushed and mixed into a homogeneous pow-
der. The MIR spectra of these samples were acquired in 
the same conditions described in section sample prepara-
tion, in triplicate. These same samples were also analysed 
by HPLC–MS/MS.
HPLC–ESI–MS/MS analysis
The analytical separations were achieved on an XBridge 
C18 column (50  ×  2.1  mm, 5  μm) coupled with an 
XBridge C18 guard column (10 × 2.1 mm, 5 μm) main-
tained at 25  °C. The mobile phase consisted of water/
acetonitrile/methanol (30:35:35 v/v/v) containing 0.1  % 
formic acid. The flow rate was 350  μL  min−1 and the 
injection volume was 5  μL. The ESI source was oper-
ated in positive mode under the following working con-
ditions: ion spray voltage of 5500 V; source temperature 
of 400  °C; nebulizer and dryer gas (nitrogen) of 40 psi; 
collision activated dissociation gas (CAD) of 10 psi and 
curtain gas (CUR) of 10 psi. Quantification was per-
formed in multiple reaction monitoring (MRM) mode, 
maintaining a dwell time of 350 ms. A mass equivalent to 
one quarter of the tablet was subjected to extraction and 
mixed with internal standard, diluted in mobile phase in 
a volumetric flask according to the appropriate concen-
tration. All samples were prepared under low light expo-
sure and filtered through a 0.22 µm PVDF syringe filter 
prior to injection.
Results
Selection of excipients and experimental design
As the quantitative levels of the excipients in the ARS-
MFQ fixed-dose combination tablets was not known, due 
to lack of access to information from the manufacturer, 
it was suggested a formulation based on the qualitative 
levels of excipients described in the leaflet and phar-
macotechnical study to build a multivariate calibration 
model. The formulation set consisted of microcrystal-
line cellulose (19.5  %-diluent), sodium croscarmellose 
(3.5  %-disintegrating agent) and magnesium stearate 
(0.5 %-lubricant).
Multivariate calibration model
The spectra of all 37 prepared samples (Fig.  3) were 
divided into 25 for the calibration set and 12 for the vali-
dation set, according to an experimental design (Fig. 2). 
The validation samples were selected in order to test the 
predictive ability of the model by ensuring a homogene-
ous and representative distribution of the two analytes 
within the analytical ranges. The use of preprocessing 
techniques in PLS model development by reflectance IR 
of powder samples is almost mandatory, due to the pres-
ence of non-linear baseline deviations. In this work, the 
most commonly used preprocessing techniques, such as 
multiplicative scatter correction (MSC), standard normal 
variate (SNV), and Savitzky-Golay first derivative with 
smoothing, were tested [29].
The best model was MIR-PLS using full spectra (4000–
400  cm−1) with first derivative followed by Savitsky-
Golay smoothing, followed by MSC (15 points in filter 
and first order polynomial fit), and mean centring (X 
block). The Y block utilized only mean centring. The PLS 
model was selected by random sub-sets cross-validation 
with three LVs (recommended as the minimum number 
of calibration and validation samples for infrared mul-
tivariate quantitative analysis). This number of LVs was 
used to estimate the smallest prediction error variance 
without significant loss of data (root mean square errors 
of cross validation (RMSECV × LV) [28].
Outliers may adversely affect the predictive ability of 
the model and therefore were investigated by analysis 
of the studentized residuals versus leverage, with limits 
of ±2.5 and 3 LV/n, respectively, considering a confidence 
limit of 95 % [28]. The values of studentized residual were 
between  ±2.5  %, and values of leverage were less than 
0.36. Outliers were not found. This model accounted for 
89.91 % of the total variance in the X block and 80.98 % 
in the Y block. The averages the RMSEC, RMSECV and 
RMSEP values for ARS and MFQ are given in Table 1.
Fig. 3 Diffuse reflectance MIR spectra of all the 37 samples of 
experimental design. Samples of calibration set are represented by 
red spectra and validation set by black spectra
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Validation of the multivariate model
Once the model was developed, its analytical validation 
is essential. For the validation process, it was consid-
ered the figures of merit recommended for multivariate 
calibration models [28], and national and international 
recommendations [30–32]. All the multivariate fig-
ures of merit estimated for this validation are listed in 
Table 1.
The precision, defined as the closeness of measure-
ments of the same concentration, was assessed at two 
levels, based on the relative standard deviation (RSD) 
for six replicates of sample at 100 % of nominal concen-
tration. The RSDs for repeatability (intra-run precision) 
were 2.73 and 2.89  % for ARS and MFQ, respectively, 
while for intermediate precision (inter-run) they were 
3.12 and 2.79  %, ARS and MFQ, respectively. All RSD 
values are less than 5  %, in accordance with Brazilian 
regulations [30]. The average trueness was evaluated 
through the parameters RMSECV, RMSEC and mainly, 
RMSEP. The estimated RMSEP for the analytes were 0.87 
and 1.93  mg/100  mg for ARS and MFQ, respectively. 
These results for trueness and precision confirm that the 
method is accurate.
The linearity was evaluated through the plot of the ref-
erence versus predicted values, as shown in (Fig. 4), and 
by verifying the random behaviours of the residual dis-
tributions for both analytes, as can be seen in Fig. 5. The 
correlation coefficients (r) were 0.90 for ARS and 0.91 for 
MFQ.
Considering the linearity and accuracy evalua-
tions, the working ranges of this method are 17.49–
29.59 mg/100 mg for ARS, and 38.56–65.23 mg/100 mg 
for MFQ.
The figures of merit selectivity (SEL), sensitivity (SEN), 
analytical sensitivity (γ), and limits of detection (LOD) 
were estimated based on the concept of net analytical 
signal (NAS), as described in the appropriate literature 
[22, 33–35]. The interpretation of SEL for multivariate 
methods is different from univariate methods, and has 
no practical application for quality control purposes. 
The SEL definition is only useful within a certain group 
of samples of similar composition, and for the developed 
method it was estimated that about 28.70 and 34.40 % of 
the analytical signal were used for measuring ARS and 
MFQ, respectively.
Since the pure SEN is not appropriate for comparison 
with other methods, their values were divided by the esti-
mative of the instrumental noise (ε = 3.7 × 10−3) and the 
more useful γ (analytical sensibility) was estimated to be 
25.47 and 35.25  mg/100  mg for ARS and MFQ, respec-
tively. The inverse of γ indicated that the method was able 
to discriminate minimum content differences between 
3.9 × 10−2 and 2.8 × 10−2 mg/100 mg for ARS and MFQ, 
respectively, considering random instrumental noise as 
the only source of errors.
Although not necessary for this kind of method, LOD 
and limit of quantification (LOQ) were also estimated 
based on the ε. The bias should be estimated only for 
the validation samples, and the values in Table  1, along 
with their standard deviation, were used in t tests with 11 
degrees of freedom and at 95 % confidence level. The esti-
mated t values were all bellow the critical t value (2.201), 
demonstrating the absence of systematic errors in the 
model. The residual prediction deviation (RPD) [35] is 
the ratio of natural variation in the samples to the size 
of probable errors occurring during the prediction, and 
it is more useful for comparing models on different data 
sets or in absolute terms. It was calculated for the calibra-
tion and validation sets, and the minimum RPD was esti-
mated as 1.56 and 3.67 for ARS and MFQ, respectively 
(for prediction in the calibration set), and 1.89 and 2.58 
for ARS and MFQ, respectively (for prediction in the vali-
dation set).
Analysis of ARS‑MFQ fixed‑dose combination tablets
The developed method was applied to the simultaneous 
quantification of ARS and MFQ in tablets (Farmanguin-
hos, RJ, Brazil) and the results were compared with those 
obtained using HPLC–MS/MS. The same samples were 
analysed by the two methods in triplicate. The predicted 
mean values and their standard deviations are shown in 
Table 2. According to the t test, there were no significant 





Figures of merit Parameter Values
ARS MFQ
Precision RSD repeatabilitya 2.73 2.89
RSD intermediatea 3.12 2.79





SA (γ)b 25.47 35.25
γ−1b 0.04 0.03





Page 6 of 8Marson et al. Malar J  (2016) 15:109 
differences between the predictions of the developed 
MIR-PLS method and HPLC–MS/MS, for both ana-
lytes (p  >  0.05), at 95  % confidence level (all estimated 
t values were below the critical t =  2.776). Therefore, it 
can be inferred that the results are statistically equivalent 
between the techniques.
Fig. 4 Plots of reference content versus predicted content of artesunate (ARS) and mefloquine (MFQ) determined by multivariate calibration 
model. Samples of calibration set are represented by black circles and validation set by red down triangles
Fig. 5 Plots of reference content versus PLS residuals for the predictions of artesunate (ARS) and mefloquine (MFQ)
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It is worth mentioning that the MIR-PLS method was 
developed based on a formulation proposed by this study. 
Even considering the possible difference between the for-
mulation proposed and samples obtained from Brazilian 
healthcare units, the method showed predictive capacity 
equivalent to the HPLC–MS/MS method.
Conclusions
This study was the first report of simultaneous quantifi-
cation of ARS and MFQ in pharmaceutical formulations 
tablets by diffuse reflectance MIR spectroscopy using 
multivariate calibration. The developed method was 
validated and shown to be a suitable technique to quan-
tify these anti-malarial agents in pharmaceutical prepa-
rations, provided results statistically similar to those 
obtained by HPLC–MS/MS, and may be successfully 
employed for quality control analysis. ARS and MFQ tab-
lets analysed by the validated method showed adequate 
quality and drug contents in agreement with the labelled 
amounts. Compared to liquid chromatography methods, 
the MIR-PLS method has advantages such as its low cost, 
rapidity and ability to provide direct solvent-free analysis. 
It may be considered suitable for routine quality control 
determinations.
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